Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee (original) (raw)
Related papers
A case-control study was conducted to estimate the association of cartilage oligomeric matrix protein (COMP) with knee osteoarthritis (OA) and to examine the potential utility of COMP as a diagnostic and prognostic biomarker in early knee OA. The COMP levels were estimated in the blood sera of 150 subjects belonging to study group (n ¼ 100) and control one (n ¼ 50). Patients with confirmed clinical isolated knee OA diagnosed through American College of Rheumatology criteria were included and were without any other cause of knee pain. ELISA was used to determine the levels of COMP, interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a). The median (range) serum COMP levels were observed to be 1117.21 ng/ml (125.03-4209.75 ng/ml) in OA patients and 338.62 ng/ml (118-589 ng/ml) in control subjects with p < 0.001. The COMP levels of study group were negatively correlated (correlation factor À0.88) with disease duration and positively correlated with age, BMI, pain score and IL-1b with correlation factors 0.86, 0.63, 0.76, and 0.79, respectively with p < 0.001. Gender differentiation was found in study group with 52% higher COMP level in males as compared to that of females. There was no significant correlation of COMP levels with radiological grading, erythrocyte sedimentation rate (ESR), hemoglobin (Hb), and TNF-a. The serum COMP levels may be used as a diagnostic OA marker along with prognostic value in determining the patients at risk of rapidly progressing this debilitating joint disease. The serum COMP level remains significantly high in first 3 years of disease duration. #
Arthritis & Rheumatism, 1999
Aim of the work: The objective of our study was to determine the utility of serum cartilage oligomeric matrix protein (COMP) as a serum biomarker for hemophilic arthropathy and to evaluate the degree of joint damage radiologically using plain X-ray and functionally using functional independence score of hemophilia (FISH) and to study their relation with COMP. Patients and methods: The study was carried out on 30 boys with hemophilic arthropathy (group I) and 20 healthy boys as control (group II). All hemophiliacs patients were scored for FISH and radiological changes (Pettersson's score). Factor activity level was measured in group I while COMP was measured in both groups. Results: The patients' age ranged from 6 to 16 years (mean 10.6 ± 2.7 years). The knee was the most commonly affected joint (83.3%). Fifteen patients (50%) had severe hemophilia, 7 had moderate and 8 had mild hemophilia. Mean serum levels of COMP in hemophilic patients (529 ± 288.1 ng/ml) were significantly higher than in control (285 ± 63.2 ng/ml) (p = 0.014). The COMP level was significantly higher in patients with severe hemophilia compared to those with moderate or mild disease (p < 0.001). The serum COMP significantly correlated with joint space narrowing (r = 0.64, p < 0.001) and with the total Pettersson score (r = 0.42, p = 0.02) and negatively with the FISH score (r = À0.44, p = 0.016). Conclusions: Serum COMP level is indicative of the amount of joint damage in patients with hemophilic arthropathy. The combined scoring of functional independence and Pettersson score in addition to serum levels of COMP give a good overview of the degree of hemophilic arthropathy.
Journal of Orthopaedic Surgery and Research
Background: The measurement of cartilage oligomeric matrix protein (COMP) has become a novel way for the diagnosis of knee osteoarthritis (OA). However, no conclusive correlation has been drawn between COMP and knee OA. The purpose of this study was to examine the utility of serum COMP as biomarker for knee OA and its relation with disease severity. Methods: A systematic search on PubMed, ScienceDirect, and EMBASE was conducted in January 2018 using certain keywords. Initial search yielded a total of 285 publications, and 35 articles were reviewed in full-text. Eventually, nine studies were included in the analysis. All the retrieved studies used Kellgren-Lawrence (K-L) classification for knee OA and provided available data of serum COMP in OA patients and healthy controls. Sensitivity analysis was performed by removing one study result at a time to detect the impact of each study have on the overall effect and to test the stability of the cumulative result. Subgroup study based on K-L grade system was also conducted to disclose the correlation between serum COMP and knee OA disease severity. Results: Pooled analysis of nine studies demonstrated a significant elevation of serum COMP in knee OA patients (SMD 0.81, [95% CI, 0.36, 1.25], P = 0.0004) compared with controls. In comparisons between K-L 1-4 and controls, significantly higher serum COMP was detected in all three subgroups except K-L grade 1 versus control. Comparisons among K-L grades 1-4 revealed significantly higher serum COMP levels in patients with more serious than less serious disease stage. However, the elevation in patients with K-L grade 3 did not reach statistical significance when compared with K-L grade 1 patients. Conclusion: The overall analysis showed significantly higher serum COMP in knee OA patients compared to controls which indicate the potential ability of serum COMP in differentiating knee OA patients from healthy subjects. Pooled statistic of our meta-analysis showed that serum COMP levels were effective in distinguishing patients with K-L ≥ 2.
How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis?
Annals of the Rheumatic Diseases, 2004
Background: No consistent relationship between the severity of symptoms of knee osteoarthritis (OA) and radiographic change has been demonstrated. Objectives: To determine the relationship between symptoms of knee OA and tibial cartilage volume, whether pain predicts loss of cartilage in knee OA, and whether change in cartilage volume over time relates to change in symptoms over the same period. Method: 132 subjects with symptomatic, early (mild to moderate) knee OA were studied. At baseline and 2 years later, participants had MRI scans of their knee and completed questionnaires quantifying symptoms of knee OA (knee-specific WOMAC: pain, stiffness, function) and general physical and mental health (SF-36). Tibial cartilage volume was determined from the MRI images. Results: Complete data were available for 117 (89%) subjects. A weak association was found between tibial cartilage volume and symptoms at baseline. The severity of the symptoms of knee OA at baseline did not predict subsequent tibial cartilage loss. However, weak associations were seen between worsening of symptoms of OA and increased cartilage loss: pain (r s = 0.28, p = 0.002), stiffness (r s = 0.17, p = 0.07), and deterioration in function (r s = 0.21, p = 0.02). Conclusion: Tibial cartilage volume is weakly associated with symptoms in knee OA. There is a weak association between loss of tibial cartilage and worsening of symptoms. This suggests that although cartilage is not a major determinant of symptoms in knee OA, it does relate to symptoms.
Indonesian Journal of Rheumatology, 2018
Background: The sensitivity of radiographic examination in the diagnosis and severity assessment of knee osteoarthritis (OA) is still low. Various attempts have been made to find more reliable indicators of cartilage damage. One potential marker is cartilage oligomeric matrix protein (COMP), a substance that in previous animal studies had been shown to be released in proportion to the extent of joint cartilage damage. Objective: To evaluate the correlation between the severity of knee OA and serum level of COMP in human with normal renal function. Methods: This was a cross-sectional study performed at the outpatient clinic in Department of Internal Medicine, Sanglah Hospital, Denpasar. The diagnosis of knee OA was based on the American College of Rheumatology (ACR) criteria. The degree of knee OA severity was determined by using the Kellgren-Lawrence criteria, while COMP values were checked by enzyme-linked immunosorbent assay (ELISA) method. Results: Forty five patients who were re...
Osteoarthritis and Cartilage, 2002
Objective: To evaluate the prognostic utility of serum COMP level measured with a new sandwich ELISA, by correlating COMP level with outcome measures of osteoarthritis (OA) progression. Design: Patients (N=48) had symptomatic primary knee OA of Kellgren-Lawrence (K-L) grade I-III and met ACR criteria. These patients were evaluated prospectively as part of a double-blind drug trial of 3 years' duration and represented the placebo arm of the study. Serum COMP levels were measured by sandwich ELISA with monoclonal antibodies 16-F12 and 17-C10 at baseline and at study end and levels were correlated with changes in (1) joint space width (JSW), (2) K-L grade, (3) Lequesne, and (4) WOMAC indices, over 3 years. Results: The change in JSW over 3 years, summed for both knees, correlated positively with serum COMP level at baseline as well as at study end. Patients were sorted by level of progression based upon a change in K-L grade summed for both knees over 3 years; patients who progressed by two K-L grades were shown to have had significantly higher COMP levels at baseline as well as at study end. Baseline and study end COMP levels did not correlate with the change of Lequesne or WOMAC indices. Baseline COMP levels correlated strongly with end serum COMP levels. Conclusion: Serum COMP has the potential to be a prognostic marker of disease progression. High COMP levels, persisting over the 3-year study period in the patients with radiographic progression, indicated differences in disease activity detectable throughout the entire follow-up interval.
Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis
Clinical Rheumatology, 2004
The cartilage oligometrix matrix protein (COMP) is a noncollagenous protein, a glycoprotein, the function of which is to bind to type II collagen fibres and stabilise the collagen fibre network in the articular cartilage. In the serum of the normal population the COMP level is 5 lg/ml. An increased level of COMP in the synovial fluid was described in the early stage of rheumatoid arthritis (RA), whereas in advanced stages of RA, the level of COMP decreased. In this study we assessed the serum COMP level in patients with RA and knee osteoarthritis (OA) and found a correlation between the serum COMP level and other markers as well as bone mass density (BMD) changes, activity of disease, disease duration and the age of the patients. The blood was collected from 30 RA patients and 30 OA patients who constituted the control group. The serum COMP level was determined using an inhibition enzyme-linked immunosorbent assay (ELISA). The average value of the serum COMP level in RA patients was 10.4±3.6 U/l. There was a correlation between the serum COMP level and the age of RA patients (p<0.005) and disease activity score (DAS) value (p<0.01). According to correlation coefficients, the serum COMP level was independent of stage of disease, number of painful and swollen joints, duration of morning stiffness, disease duration and titre of the Waaler-Rose test. The influence of rheumatoid nodule presence on the serum COMP level was shown (p<0.05). In RA patients with erythrocyte sedimentation rate (ESR) values below 20 mm/h compared with patients with ESR values over 60 mm/h, the serum COMP level was observed to be significantly lower (p<0.05). The average value of COMP in OA patients was 10.4±2.7 U/l. No correlation was found between the serum COMP level and patients' age and disease duration. There was a correlation between the serum COMP level and Western Ontario and McMaster Universities (WOMAC) index pain scale for the lower limbs (p<0.005) and T-score value of densitometry examinations (p<0.036) in OA patients. No statistical differences were found between the average serum COMP level in RA and OA patients.
A new marker for osteoarthritis: Cross-sectional and longitudinal approach
Arthritis & Rheumatism, 2004
Methods. The study population consisted of a sample of 1,235 men and women ages >55 years who were enrolled in the Rotterdam Study (a populationbased cohort study) and who were followed up for a mean of 6.6 years. Prevalent radiographic OA was defined as a Kellgren/Lawrence score >2; progression of radiographic OA was defined as a decrease in joint space width.